Archive for the ‘In the News’ Category

You are here: Home » In the News » "

Ariana Pharma, société spécialiste de l’analyse des données cliniques et des tests diagnostiques pour la médecine personnalisée, vient d’annoncer le lancement du projet ExtempoRMN. A travers ce projet qui associe cette spin-off de l’Institut Pasteur au groupe d’instrumentation scientifique Bruker BioSpin, aux Hôpitaux universitaires de Strasbourg et au laboratoire Icube de l’université de Strasbourg, l’objectif est de faciliter la distinction des tissus tumoraux des tissus sains environnants lors de la réalisation de chirurgie des tumeurs cérébrales. (more…)

Read more

L’entreprise parisienne Ariana Pharma, spécialisée dans les outils informatiques d’aide à la décision clinique, a été retenue pour participer au projet alsacien ExtempoRMN. Celui-ci vise à développer une méthode innovante permettant d’établir le diagnostic des tissus cancéreux en temps réel. Quelques mois auparavant, Ariana Pharma était sélectionnée dans le cadre de l’essai clinique international Winther initié par le MD Anderson Center et l’Institut Gustave Roussy, qui offre pour la première fois, à chaque patient inclus, un traitement personnalisé basé sur ses analyses biologiques. Mohammad Afshar, CEO d’Ariana Pharma, détaille le rôle de sa société dans chacune de ces collaborations et les enjeux derrière les ruptures technologiques en gestation. (more…)

Read more

When Ariana Pharma announced this summer that the WIN Consortium had chosen it to develop new personalized cancer medicine software through the consortium’s WINTHER trial, it wasn’t just a validation of Paris-based Ariana’s data management skills in life science, notes Dr. David Morley, Ariana’s vice president of computational technology — it was also a sign of how much data mining has shifted from its early beginnings in drug discovery to something much more oriented toward clinical trials. (more…)

Read more

The advent of targeted cancer therapies has necessitated the development of companion diagnostics to identify those patients whose genetic makeup will allow them to benefit. But a patient’s gene signature is only one factor of many capable of affecting their response to a treatment. There is a demand, says Mohammad Afshar, CEO of Ariana Pharma, for a tool that will analyse all of a patient’s characteristics at once – physiological, genetic, genomic, proteomic – and assign them the drug or procedure that will benefit them most. He tells EP Vantage: “What we’re working on here is the ability to look at all the data that is available on these particular tumours and patients, and combine this information together to identify the best treatment.” (more…)

Read more

WIN global initiative aims to significantly improve clinical care and outcomes for cancer patients through fundamental changes in trial design and personalized treatment options. The WIN Consortium has chosen Ariana Pharma to develop and globally commercialize ground-breaking decision support software to help clinicians choose the best therapies for cancer patients. The software will be developed through the WINTHER trial, the first state of the art clinical trial in personalized cancer medicine. (more…)

Read more

Paris, France, and Cambridge, US, 25 March 2013 – Ariana Pharma, a company that develops innovative data analysis and diagnostic testing solutions for the pharmaceutical and biotechnological industries, today announced its participation in the IMODI consortium. The company is to receive €1,2M in funding under the French Government’s “Investing for the Future” program. (more…)

Read more

Ariana continues global expansion from US to Japan with KEM(R) data analytics software and services technology. Ariana Pharma, the premium provider of advanced, non-statistical clinical data and biomarker analytics technology across life science industries as well as the FDA, today announces the signing of an exclusive Japanese distribution agreement with CTC Laboratory Systems Corporation (CTCLS), the Japanese supplier of services for R&D solutions. (more…)

Read more